

Ingela Franck Lissbrant

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1731143/publications.pdf>

Version: 2024-02-01

32
papers

584
citations

759233

12
h-index

610901

24
g-index

32
all docs

32
docs citations

32
times ranked

1074
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort. <i>European Urology</i> , 2016, 69, 1135-1141. | 1.9 | 104 |
| 2 | Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer. <i>European Urology</i> , 2015, 68, 53-58. | 1.9 | 69 |
| 3 | Population-based study of long-term functional outcomes after prostate cancer treatment. <i>BJU International</i> , 2016, 117, E36-45. | 2.5 | 58 |
| 4 | Population-based study on use of chemotherapy in men with castration resistant prostate cancer. <i>Acta Oncologica</i> , 2013, 52, 1593-1601. | 1.8 | 44 |
| 5 | Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study. <i>European Urology</i> , 2018, 73, 502-511. | 1.9 | 37 |
| 6 | Dashboard report on performance on select quality indicators to cancer care providers. <i>Scandinavian Journal of Urology</i> , 2016, 50, 21-28. | 1.0 | 30 |
| 7 | Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study. <i>European Urology</i> , 2017, 72, 920-928. | 1.9 | 21 |
| 8 | Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. <i>European Urology</i> , 2017, 72, 125-134. | 1.9 | 21 |
| 9 | Prostate cancer diagnosis, staging, and treatment in Sweden during the first phase of the COVID-19 pandemic. <i>Scandinavian Journal of Urology</i> , 2021, 55, 184-191. | 1.0 | 21 |
| 10 | Mini Review on the Use of Clinical Cancer Registers for Prostate Cancer: The National Prostate Cancer Register (NPCR) of Sweden. <i>Frontiers in Medicine</i> , 2019, 6, 51. | 2.6 | 18 |
| 11 | Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 579-584. | 1.8 | 16 |
| 12 | Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study. <i>Pathology</i> , 2017, 49, 715-720. | 0.6 | 14 |
| 13 | Temporal changes in survival in men with <i>de novo</i> metastatic prostate cancer: nationwide population-based study. <i>Acta Oncologica</i> , 2020, 59, 106-111. | 1.8 | 12 |
| 14 | Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, population-based study in Sweden. <i>BJU International</i> , 2020, 126, 142-151. | 2.5 | 12 |
| 15 | Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden. <i>Scandinavian Journal of Urology</i> , 2018, 52, 143-150. | 1.0 | 11 |
| 16 | Set-up and preliminary results from the Patient-overview Prostate Cancer. Longitudinal registration of treatment of advanced prostate cancer in the National Prostate Cancer Register of Sweden. <i>Scandinavian Journal of Urology</i> , 2020, 54, 227-234. | 1.0 | 11 |
| 17 | Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998–2016. <i>Acta Oncologica</i> , 2020, 59, 549-557. | 1.8 | 11 |
| 18 | The use of palliative medications before death from prostate cancer: Swedish population-based study with a comparative overview of European data. <i>European Journal of Cancer</i> , 2018, 88, 101-108. | 2.8 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden. <i>Scandinavian Journal of Urology</i> , 2021, 55, 1-8. | 1.0 | 10 |
| 20 | Public online reporting from a nationwide population-based clinical prostate cancer register. <i>BJU International</i> , 2018, 122, 8-10. | 2.5 | 8 |
| 21 | Observational study on time on treatment with abiraterone and enzalutamide. <i>PLoS ONE</i> , 2020, 15, e0244462. | 2.5 | 8 |
| 22 | Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden. <i>Acta Oncologica</i> , 2021, 60, 459-465. | 1.8 | 7 |
| 23 | The National Prostate Cancer Register of Sweden. <i>Tijdschrift Voor Urologie</i> , 2017, 7, 50-59. | 0.1 | 6 |
| 24 | Rapid ascertainment of uptake of a new indication for abiraterone by use of three nationwide health care registries in Sweden. <i>Acta Oncologica</i> , 2021, 60, 56-60. | 1.8 | 6 |
| 25 | The Value of Real-World Data in Understanding Prostate Cancer Risk and Improving Clinical Care: Examples from Swedish Registries. <i>Cancers</i> , 2021, 13, 875. | 3.7 | 6 |
| 26 | Comparative Effectiveness of Different Radical Radiotherapy Treatment Regimens for Prostate Cancer: A Population-Based Cohort Study. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa006. | 2.9 | 5 |
| 27 | Time on treatment with abiraterone and enzalutamide in the Patient-overview Prostate Cancer in The National Prostate Cancer Register of Sweden. <i>Acta Oncologica</i> , 2021, 60, 1589-1596. | 1.8 | 3 |
| 28 | Time on treatment with abiraterone in men with <i>de novo</i> metastatic castration sensitive prostate cancer: a drug utilization study. <i>Acta Oncologica</i> , 2022, 61, 328-332. | 1.8 | 3 |
| 29 | Lag time to adverse events after radical prostatectomy and curative radiotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 49-49. | 1.6 | 1 |
| 30 | Time difference in retrieving clinical information in Patient-overview Prostate Cancer compared to electronic health records. <i>Scandinavian Journal of Urology</i> , 2022, 56, 95-101. | 1.0 | 1 |
| 31 | Castration is a prerequisite for the inhibitory effect of metronomic chemotherapy on the growth of experimental castration-resistant prostate cancer. <i>Acta Oncologica</i> , 2018, 57, 895-901. | 1.8 | 0 |
| 32 | Bone scan index as a biomarker to predict outcome in real-life mCRPC patients on abiraterone acetate: A multicenter study. <i>Journal of Clinical Oncology</i> , 2015, 33, 217-217. | 1.6 | 0 |